93346 Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 

Controlled substance Drug code Schedule 

Gamma Hydroxybutyric Acid ..................................................................................................................................... 2010 I 

Lysergic acid diethylamide ........................................................................................................................................ 7315 I 

Marihuana .................................................................................................................................................................. 7360 I 

Tetrahydrocannabinols .............................................................................................................................................. 7370 I 

3,4-Methylenedioxyamphetamine .............................................................................................................................. 7400 I 

3,4-Methylenedioxymethamphetamine ...................................................................................................................... 7405 I 

5-Methoxy-N–N-dimethyltryptamine .......................................................................................................................... 7431 I 

Alpha-Methyltryptamine ............................................................................................................................................. 7432 I 

Bufotenine .................................................................................................................................................................. 7433 I 

Diethyltryptamine ....................................................................................................................................................... 7434 I 

Dimethyltryptamine .................................................................................................................................................... 7435 I 

Psilocybin ................................................................................................................................................................... 7437 I 

Psilocyn ..................................................................................................................................................................... 7438 I 

2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) ............................................................................................ 7508 I 

2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) ........................................................................................................... 7517 I 

Heroin ........................................................................................................................................................................ 9200 I 

Morphine .................................................................................................................................................................... 9300 II 

The company plans to synthesize the 

listed controlled substances for 

distribution to its customers. In 

reference to drug codes 7360 

(Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Matthew Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2024–27674 Filed 11–25–24; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1446] 

Importer of Controlled Substances 

Application: National Center for 

Natural Products Research 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: National Center for Natural 

Products Research has applied to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplementary Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants, therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before December 26, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 26, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on September 16, 2024, 

National Center for Natural Products 

Research, 806 Hathorn Road, 135 Coy 

Waller Lab, University, Mississippi 

38677 applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Marihuana ...................... 7360 I 

Tetrahydrocannabinols .. 7370 I 

The company plans to acquire new 

genetic materials with improved 

cannabinoids for research and 

manufacturing purposes. No other 

activities for these drug codes are 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2024–27694 Filed 11–25–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1458] 

Bulk Manufacturer of Controlled 

Substances Application: Isosciences, 

LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Isosciences, LLC has applied 

to be registered as a bulk manufacturer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants, therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before January 27, 2025. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 27, 2025. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 


lotter on DSK11XQN23PROD with NOTICES1

I I 
Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 93347 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on October 28, 2024, 

Isosciences, LLC, 340 Mathers Road, 

Ambler, Pennsylvania 19002–3420 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug code Schedule 

Cathinone ......................................................................................................................................................................... 1235 I 

Methcathinone .................................................................................................................................................................. 1237 I 

Lysergic acid diethylamide ............................................................................................................................................... 7315 I 

Marihuana ......................................................................................................................................................................... 7360 I 

Tetrahydrocannabinols ..................................................................................................................................................... 7370 I 

3,4-Methylenedioxyamphetamine ..................................................................................................................................... 7400 I 

3,4-Methylenedioxy-N-ethylamphetamine ........................................................................................................................ 7404 I 

3,4-Methylenedioxymethamphetamine ............................................................................................................................. 7405 I 

5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................. 7431 I 

Alpha-methyltryptamine .................................................................................................................................................... 7432 I 

Bufotenine ........................................................................................................................................................................ 7433 I 

Diethyltryptamine .............................................................................................................................................................. 7434 I 

Dimethyltryptamine ........................................................................................................................................................... 7435 I 

Psilocybin ......................................................................................................................................................................... 7437 I 

Psilocyn ............................................................................................................................................................................ 7438 I 

5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................................. 7439 I 

Dihydromorphine .............................................................................................................................................................. 9145 I 

Heroin ............................................................................................................................................................................... 9200 I 

Nicocodeine ...................................................................................................................................................................... 9309 I 

Nicomorphine ................................................................................................................................................................... 9312 I 

Normorphine ..................................................................................................................................................................... 9313 I 

Thebacon .......................................................................................................................................................................... 9315 I 

Normethadone .................................................................................................................................................................. 9635 I 

Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) .................................................................................. 9811 I 

Para-Fluorofentanyl .......................................................................................................................................................... 9812 I 

3-Methylfentanyl ............................................................................................................................................................... 9813 I 

Alpha-methylfentanyl ........................................................................................................................................................ 9814 I 

Acetyl-alpha-methylfentanyl ............................................................................................................................................. 9815 I 

N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide ........................................................................................ 9816 I 

Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ................................................................................ 9821 I 

Butyryl Fentanyl ................................................................................................................................................................ 9822 I 

4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .......................................... 9824 I 

2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide .......................................................................................... 9825 I 

Beta-hydroxyfentanyl ........................................................................................................................................................ 9830 I 

Beta-hydroxy-3-methylfentanyl ......................................................................................................................................... 9831 I 

Alpha-methylthiofentanyl .................................................................................................................................................. 9832 I 

3-Methylthiofentanyl ......................................................................................................................................................... 9833 I 

Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) .............................................................. 9834 I 

Thiofentanyl ...................................................................................................................................................................... 9835 I 

Beta-hydroxythiofentanyl .................................................................................................................................................. 9836 I 

N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide ........................................................................... 9843 I 

Amphetamine ................................................................................................................................................................... 1100 II 

Methamphetamine ............................................................................................................................................................ 1105 II 

Codeine ............................................................................................................................................................................ 9050 II 

Dihydrocodeine ................................................................................................................................................................. 9120 II 

Oxycodone ....................................................................................................................................................................... 9143 II 

Hydromorphone ................................................................................................................................................................ 9150 II 

Hydrocodone .................................................................................................................................................................... 9193 II 

Isomethadone ................................................................................................................................................................... 9226 II 

Methadone ........................................................................................................................................................................ 9250 II 

Methadone intermediate ................................................................................................................................................... 9254 II 

Morphine ........................................................................................................................................................................... 9300 II 

Thebaine ........................................................................................................................................................................... 9333 II 

Levo-alphacetylmethadol .................................................................................................................................................. 9648 II 

Oxymorphone ................................................................................................................................................................... 9652 II 

Thiafentanil ....................................................................................................................................................................... 9729 II 

Alfentanil ........................................................................................................................................................................... 9737 II 

Sufentanil .......................................................................................................................................................................... 9740 II 

Carfentanil ........................................................................................................................................................................ 9743 II 

Fentanyl ............................................................................................................................................................................ 9801 II 


lotter on DSK11XQN23PROD with NOTICES1
93348 Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 

The company plans to bulk 

manufacture the listed controlled 

substances to be used in analytical 

testing. In reference to drug codes 7360 

(Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Matthew Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2024–27693 Filed 11–25–24; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1117–0049] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Revision 

Without Change of a Previously 

Approved Collection Recordkeeping 

for Electronic Prescriptions for 

Controlled Substances 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Drug Enforcement 

Administration (DEA), will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

January 27, 2025. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact 

Heather E. Achbach, Regulatory Drafting 

and Policy Support Section, Drug 

Enforcement Administration; Mailing 

Address: 8701 Morrissette Drive, 

Springfield, Virginia 22152; Telephone: 

(571) 776–3882; Email: 

Heather.E.Achbach@dea.gov or 

DEA.PRA@dea.gov. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the Bureau of Justice 

Statistics, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

1. Type of Information Collection: 

Revision of a currently approved 

collection. 

2. Title of the Form/Collection: 

Recordkeeping for Electronic 

Prescriptions for Controlled Substances. 

3. The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

No form number is associated with this 

collection. The applicable component 

within the Department of Justice is the 

Drug Enforcement Administration, 

Diversion Control Division. 

4. Affected public who will be asked 

or required to respond, as well as a brief 

abstract: 

Affected public (Primary): Business or 

other for-profit. 

Affected public (Other): Not-for-profit 

institutions; Federal, State, local, and 

tribal governments. 

Abstract: DEA is requiring that each 

registered practitioner apply to an 

approved credential service provider 

approved to obtain identity proofing 

and a credential. Hospitals and other 

institutional practitioners may conduct 

this process in-house as part of their 

credentialing. For practitioners 

currently working at or affiliated with a 

registered hospital or clinic, the 

hospital/clinic have to check a 

government-issued photographic 

identification. This may be done when 

the hospital/clinic issues credentials to 

new hires or newly affiliated 

physicians. For individual practitioners, 

two people need to enter logical access 

control data to grant permissions for 

practitioners authorized to approve and 

sign controlled substance prescriptions 

using the electronic prescription 

application. For institutional 

practitioners, logical access control data 

is entered by two people from an entity 

within the hospital/clinic that is 

separate from the entity that conduct 

identity proofing in-house. Similarly, 

pharmacies have to set logical access 

controls in the pharmacy application so 

that only authorized employees have 

permission to annotate or alter 

prescription records. Finally, if the 

electronic prescription or pharmacy 

application generates an incident report, 

practitioners, hospitals/clinics, and 

pharmacies have to review the incident 

report to determine if the event 

identified by the application represents 

a security incident. 

5. An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: The DEA estimates that 

158,884 registrants participate in this 

information collection, taking an 

estimated 40 minutes for Practitioner, 

128 minutes for Hospital/Clinic, and 20 

minutes for Pharmacy. 

6. An estimate of the total public 

burden (in hours) associated with the 

proposed collection: DEA estimates that 

this collection takes 107,733 annual 

burden hours. 

7. An estimate of the total annual cost 

burden associated with the collection, if 

applicable: $0. 

TOTAL BURDEN HOURS

Activity Number of 

respondents Frequency Total annual responses Time per response 

Total annual 

burden 

(hours) 

Practitioner ......................................................................... 154,571 1 154,571 0.67 (40 minutes) ... 103,563 

Hospital/Clinic .................................................................... 1,526 1 1,526 2.13 (128 minutes) 1,526 

Pharmacy ........................................................................... 2,787 1 2,787 0.33 (20 minutes) ... 2,787 

Unduplicated Totals .................................................... 158,884 N/A 158,884 1.043 ...................... 107,733 


lotter on DSK11XQN23PROD with NOTICES1